[F18] FDG-PET/CT for manual or semiautomated GTV delineation of the primary tumor for radiation therapy planning in patients with esophageal cancer: is it useful?
Contouring
Gross tumor volume
Interobserver variability
PERCIST-TLG
Radiotherapy
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
08
06
2020
accepted:
29
09
2020
pubmed:
27
10
2020
medline:
1
4
2022
entrez:
26
10
2020
Statut:
ppublish
Résumé
Target volume definition of the primary tumor in esophageal cancer is usually based on computed tomography (CT) supported by endoscopy and/or endoscopic ultrasound and can be difficult given the low soft-tissue contrast of CT resulting in large interobserver variability. We evaluated the value of a dedicated planning [F18] FDG-Positron emission tomography/computer tomography (PET/CT) for harmonization of gross tumor volume (GTV) delineation and the feasibility of semiautomated structures for planning purposes in a large cohort. Patients receiving a dedicated planning [F18] FDG-PET/CT (06/2011-03/2016) were included. GTV was delineated on CT and on PET/CT (GTV 45 cases were evaluated. Mean GTV We were not able to show that the integration of PET/CT for GTV delineation of the primary tumor resulted in reduced interobserver variability. The PERCIST-TLG algorithm seemed most promising compared to other thresholds for further evaluation of semiautomated delineation of esophageal cancer.
Sections du résumé
BACKGROUND
Target volume definition of the primary tumor in esophageal cancer is usually based on computed tomography (CT) supported by endoscopy and/or endoscopic ultrasound and can be difficult given the low soft-tissue contrast of CT resulting in large interobserver variability. We evaluated the value of a dedicated planning [F18] FDG-Positron emission tomography/computer tomography (PET/CT) for harmonization of gross tumor volume (GTV) delineation and the feasibility of semiautomated structures for planning purposes in a large cohort.
METHODS
Patients receiving a dedicated planning [F18] FDG-PET/CT (06/2011-03/2016) were included. GTV was delineated on CT and on PET/CT (GTV
RESULTS
45 cases were evaluated. Mean GTV
CONCLUSION
We were not able to show that the integration of PET/CT for GTV delineation of the primary tumor resulted in reduced interobserver variability. The PERCIST-TLG algorithm seemed most promising compared to other thresholds for further evaluation of semiautomated delineation of esophageal cancer.
Identifiants
pubmed: 33104815
doi: 10.1007/s00066-020-01701-0
pii: 10.1007/s00066-020-01701-0
pmc: PMC8397654
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
780-790Informations de copyright
© 2020. The Author(s).
Références
N Engl J Med. 1992 Jun 11;326(24):1593-8
pubmed: 1584260
Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):354-61
pubmed: 18931839
Clin Transl Oncol. 2018 Nov;20(11):1460-1466
pubmed: 29721766
Nuklearmedizin. 2012;51(3):101-10
pubmed: 22446512
Clin Transl Radiat Oncol. 2018 Oct 26;14:33-39
pubmed: 30519647
Radiat Oncol. 2019 Sep 4;14(1):163
pubmed: 31484542
Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):911-20
pubmed: 26104943
Radiother Oncol. 2009 Dec;93(3):441-6
pubmed: 19682760
Radiat Oncol. 2013 Jul 12;8:180
pubmed: 23848981
J Med Imaging Radiat Oncol. 2015 Jun;59(3):338-45
pubmed: 25708154
Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1235-41
pubmed: 19910143
Dis Esophagus. 2010 Aug;23(6):493-501
pubmed: 20113320
Strahlenther Onkol. 2018 Feb;194(2):116-124
pubmed: 28916906
Radiat Oncol. 2018 May 16;13(1):93
pubmed: 29769143
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1057-63
pubmed: 20199850
J Nucl Med. 2006 Aug;47(8):1255-9
pubmed: 16883002
Radiat Oncol. 2018 Mar 2;13(1):37
pubmed: 29499730
J Radiat Res. 2019 May 1;60(3):348-352
pubmed: 30864652
J Clin Oncol. 2004 Sep 15;22(18):3805-12
pubmed: 15365078
Strahlenther Onkol. 2018 May;194(5):435-443
pubmed: 29349603
Oncol Rep. 2008 Oct;20(4):857-62
pubmed: 18813827
Anticancer Res. 2008 May-Jun;28(3B):1867-73
pubmed: 18630473
Radiother Oncol. 2015 Aug;116(2):269-75
pubmed: 26364886
Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):136-41
pubmed: 18538492
Strahlenther Onkol. 2005 Aug;181(8):483-99
pubmed: 16044216
Radiother Oncol. 2010 Nov;97(2):165-71
pubmed: 20541273
J Gastrointest Surg. 2004 Dec;8(8):988-96
pubmed: 15585386
Radiat Oncol. 2014 Aug 29;9:191
pubmed: 25175056
Strahlenther Onkol. 2017 Oct;193(10):791-799
pubmed: 28770295
J Med Imaging Radiat Oncol. 2016 Aug;60(4):520-7
pubmed: 27197751
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Clin Oncol (R Coll Radiol). 2008 Oct;20(8):631-8
pubmed: 18755578